Hallazgo, Retchel .
HRN: 22-21-71 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/26/2022
CO-AMOXICLAV 625MG (TAB)
12/26/2022
01/02/2023
ORAL
625mg
Q12
T/C Endometritis
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes